Novira Therapeutics

Novira Therapeutics Announces Acquisition Agreement with Johnson & Johnson See more here

Novira Therapeutics Announces Presentation of Phase Ia Safety and Pharmacokinetic Data for NVR 3-778 Read more here

Novira Therapeutics Announces Successful Completion of Phase 1a Clinical Study of NVR-1221 and Commencement of Phase 1b Clinical Studies Read more here

Novira Therapeutics Announces Appointment of Roger J. Pomerantz, M.D., F.A.C.P., as Chair of Scientific Advisory Board Read more here

Novira Therapeutics Begins Phase 1a Clinical Study of NVR–1221 for the Treatment of Chronic Hepatitis B (HBV) Infection Read more here

Novira Names Christian Schade as Chief Executive Officer Read more here

Novira Therapeutics Expands Management Team Read more here

Novira Therapeutics Completes $25 Million Series A Financing Read more here

Philly Inc: Small Businesses Solving Big Problems Read more here

Novira Therapeutics raises $23M Read more here